| Patents for A61P 41 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution (3,707) |
|---|
| 11/03/2005 | US20050245537 Use of compounds having ccr antagonism |
| 11/03/2005 | US20050244358 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery |
| 11/03/2005 | CA2564161A1 Melatonin and its use in preventing postoperative complications |
| 11/02/2005 | EP1591135A1 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 11/02/2005 | EP1591118A1 Use of melatonin in preventing postoperative complications |
| 11/02/2005 | EP1591116A1 Inhibitor for perioperative blood sugar elevation |
| 11/01/2005 | US6960609 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents |
| 10/27/2005 | US20050238726 N-methyl D-aspartic acid (NMDA) receptor antagonism; neuroprotection |
| 10/27/2005 | US20050238623 Method for treating mammals with modified mammalian blood |
| 10/27/2005 | CA2505469A1 Drug delivery device comprising a bilayered polymeric coating having a cell cycle inhibitor that acts selectively at the g1 phase of the cell cycle incorporated into the first polymer coating layer |
| 10/26/2005 | CN1688572A Piperidinyl targeting compounds that selectively bind integrins |
| 10/26/2005 | CN1688550A 2, 5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 |
| 10/26/2005 | CN1688549A Compound having TGF-beta inhibitory activity and medicinal composition containing the same |
| 10/26/2005 | CN1688198A Induction of gene expression using a high concentration sugar mixture |
| 10/26/2005 | CN1224598C Naphthalene derivatives |
| 10/26/2005 | CN1224389C The use of scopolamine salts |
| 10/25/2005 | US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 10/25/2005 | US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock |
| 10/20/2005 | WO2005097814A2 Composition and method for inhibiting platelet aggregation |
| 10/20/2005 | US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals |
| 10/20/2005 | US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 10/20/2005 | US20050234029 Compounds |
| 10/20/2005 | US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 10/20/2005 | CA2561958A1 Composition and method for inhibiting platelet aggregation |
| 10/19/2005 | EP1339438B1 Preventing transplant rejection in the eye |
| 10/19/2005 | EP1292340B1 Transfection system |
| 10/19/2005 | CN1684695A Vitreoretinal tamponades based on fluorosilicone fluids |
| 10/18/2005 | US6955682 Wound closure system and methods |
| 10/13/2005 | WO2005094912A1 Transplantation graft with enhanced angiogenic effect |
| 10/13/2005 | US20050228036 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 10/12/2005 | CN1679937A Compositions and methods for treating or preventing inflammatory diseases |
| 10/06/2005 | US20050222083 Thiol-modified hyaluronan |
| 10/06/2005 | US20050221347 Inhibitors of binding between proteins and macromolecular ligands |
| 10/05/2005 | EP1582210A2 Compositions and methods for treating or preventing surgical adhesions |
| 10/05/2005 | EP1581254A2 Pharmacological vitreolysis |
| 10/05/2005 | EP1581165A2 Novel factor viia inhibiting compounds |
| 10/05/2005 | EP1263430B1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 10/05/2005 | EP1183233B1 Bradykinin receptor antagonists |
| 09/28/2005 | CN1672688A Medical composite chitinamine gel |
| 09/27/2005 | US6949525 In particular the treatment of osteochondral lesions associated with osteoarthritis by means of intraarticular application of a mixture of hyaluronate and chondroitin sulfate |
| 09/22/2005 | WO2005087289A1 Adhesion preventive material |
| 09/22/2005 | US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/21/2005 | CN1671716A Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
| 09/15/2005 | US20050203065 Use of A2b adenosine receptor antagonists such as 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.2]oct-1-yl]-propionic acid (BG 9928) |
| 09/15/2005 | US20050202394 Organ arrest, protection, preservation and recovery |
| 09/15/2005 | US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 09/14/2005 | EP1572175A1 Formulation, which can be administered gastrointestinally, containing green tea extract and an no donor |
| 09/14/2005 | EP1030676B1 Bonding of cartilaginous matrices using isolated chondrocytes |
| 09/14/2005 | CN1668296A Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 09/13/2005 | US6943146 Control cell proliferation, cell differentiation; culture product |
| 09/09/2005 | CA2554908A1 Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration |
| 09/09/2005 | CA2554823A1 Nk-1 receptor antagonists to improve anesthesia recovery |
| 09/07/2005 | CN1665803A Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| 09/07/2005 | CN1665800A Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| 09/07/2005 | CN1217657C Method of improving survival of patients |
| 09/01/2005 | CA2557333A1 Antifungal peptides |
| 08/31/2005 | CN1662514A Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 08/31/2005 | CN1660102A Ligustrazine microcapsule and preparation method |
| 08/24/2005 | EP1565199A2 Therapeutic polypeptides,nucleic acids encoding same, and methods of use |
| 08/18/2005 | US20050182064 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 08/18/2005 | CA2554683A1 Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers |
| 08/17/2005 | EP1289951B1 Growth hormone secretagogues |
| 08/17/2005 | CN1655761A Modified release pharmaceutical formulation |
| 08/11/2005 | US20050176927 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; diagnosis |
| 08/11/2005 | US20050176813 Modulating the potassium ion channel activity of T-cells; autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or transplant rejection; synthesis by reaction of an acetophenone such as khellinone with an aryl aldehyde |
| 08/09/2005 | US6927219 Secondary amides such as N-Adamantan-1-methyl-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H- (1,2,4)triazin-2-yl)-benzamide used as antagonists for biological receptors; antiinflammatiory, anticarcinogenic or antiischemic agents |
| 08/09/2005 | US6926898 Albumin fusion proteins |
| 08/04/2005 | US20050171083 Modified release pharmaceutical formulation |
| 08/04/2005 | US20050171049 Compounds for the treatment of ischemia |
| 08/03/2005 | EP1558080A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 08/03/2005 | CN1649895A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 08/03/2005 | CN1649857A Hydroxamic acid derivatives |
| 08/03/2005 | CN1649848A Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF) |
| 08/03/2005 | CN1649843A Novel chalcone derivatives and uses thereof |
| 08/02/2005 | US6924266 NTP-peptides and method for removal of tumors |
| 07/28/2005 | WO2005007211A3 Medical devices with proteasome inhibitors for the treatment of restenosis |
| 07/28/2005 | US20050164981 Injection of a synthetic synovial fluid containing one or more phosphatides, such as dipalmitoyl phosphatidylcholine, and a biodegradable dextran-glycidyl methacrylate copolymer hydrogel; phosphatides are incorporated into the cartilage of the arthritic, injured, or diseased joint; antiarthritic agents |
| 07/28/2005 | US20050163781 uses of inhibitors against hypoxia-induced genes for the manufacture of a medicament to prevent and/or to suppress post-operative/post-wounding adhesions formation; peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma |
| 07/27/2005 | EP1557183A1 Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis |
| 07/27/2005 | EP1556033A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 07/27/2005 | EP0799051B1 Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
| 07/27/2005 | CN1646146A Methods of treating vascular disease |
| 07/21/2005 | US20050158721 Using overexpression of senescence-associated genes as diagnostic/prognostic indicator of organ rejection/failure |
| 07/21/2005 | US20050158360 From a two-layered polymeric matrix including incompatible polymers, the top layer controls elution rate of said drugs; e.g. fluoropolymer layer covered with a polyacrylate top layer; stents, anastomotic devices |
| 07/21/2005 | US20050158282 epidermal growth factor (EGF) producing Lactococcus lactis and Lactobacillus casei ( lactic acid bacterium); useful to treat Short Bowel Syndrome; increase intestinal villi height |
| 07/20/2005 | EP1555031A1 Angiogenesis inducer |
| 07/14/2005 | WO2005063278A1 Surface protection of exposed biological tissues |
| 07/14/2005 | WO2005009480A3 Implants containing codrugs |
| 07/14/2005 | CA2550872A1 Surface protection of exposed biological tissues |
| 07/13/2005 | EP1551430A2 Botulinum toxin dental therapies and procedures |
| 07/13/2005 | EP1248636B1 Dextrin containing compositions for prevention of adhesions |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 07/13/2005 | CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/06/2005 | EP1549632A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| 07/06/2005 | EP1549277A1 Induction and maintenance of tolerance to composite tissue allografts |
| 07/06/2005 | CN1634124A Application of sodium hyaluronate in the process for preparing medical apparatus for preventing and treating adhesion due to pleurisy and pericarditis |
| 06/30/2005 | WO2003064629A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/30/2005 | US20050143412 Controlled cessation of heart beat during cardiac surgeries by electrical stimulation of the vagus nerve and administration of a combination of drugs; improved surgical technique; Controlled intermittent asystole |
| 06/30/2005 | US20050143368 Chemical compounds |
| 06/30/2005 | US20050142118 Human cord blood derived unrestricted somatic stem cells (USSC) |